Summary of Utilization Management (UM) Program Changes

January #2 2021

Brand Name	Generic Name	Utilization Update Summary	Type	Effective Date
Dojolvi	triheptanoin	Dojolvi is indicated for long-chain fatty aside oxidation disorder (LC-FAOD). Initial criteria requires: **1)** Diagnosis of a long-chain fatty acid oxidation disorder (LC-FAOD) AND **2)** Disease has been molecularly confirmed (i.e., genetic testing) AND **3)** Not used with any other medium-chain triglyceride (MCT) product AND **4)** Prescribed by a clinical specialist knowledgeable in appropriate disease-related dietary management (e.g., geneticist, cardiologist, gastroenterologist, etc.)	New	4/01/2021
Mycapssa (in Octreotide Products)	octreotide	New oral octreotide capsule approved as long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. Initial criteria requires: **1)** Diagnosis of acromegaly **2)** One of the following: *either* inadequate response to surgery or pituitary radiation therapy, *or* not a candidate for surgical resection or pituitary radiation therapy; **3)** Patient has responded to and tolerated treatment with octreotide or lanreotide.	Update	4/01/2021
Botox	onabotulinumtoxin A	Expanded indication: treatment of spasticity in patients 2 years of age and older. Modified criteria to simply state diagnosis of spasticity (remove reference to lower and upper limb spasticity).	Update	4/01/2021

Dysport	abobotulinumtoxin A	Expanded indication: treatment of spasticity in patients 2 years of age and older. Modified criteria to simply state diagnosis of spasticity (remove reference to lower and upper limb spasticity).	Update	4/01/2021
Tremfya	guselkumab	New indication for treatment of adult patients with active psoriatic arthritis. Initial criteria requires: **1)** diagnosis of active psoriatic arthritis (PsA) **2)** Prescribed by dermatologist or rheumatologist.	Update	2/18/2021
Actemra	tocilizumab	Update to remove Simponi Aria as one of the first line trial and failure options for rheumatoid arthritis indication. Simponi is still an option.	Update	4/01/2021
Orencia	abatacept	Update to remove Simponi Aria one of the first line trial and failure options for rheumatoid arthritis, psoriatic arthritis indication. Simponi is still an option.	Update	4/01/2021
Enbrel	etanercept	Update to remove Simponi Aria as one of the first line trial and failure options for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis indications. Simponi is still an option. The criteria will no longer have separate sections based on age.	Update	4/01/2021
Kevzara	sarilumab	Update to remove Simponi Aria as one of the first line trial and failure options for rheumatoid arthritis indication. Simponi is still an option.	Update	4/01/2021
Kineret	anakinra	Update to remove Simponi Aria as one of the first line trial and failure options for rheumatoid arthritis indication. Simponi is still an option.	Update	4/01/2021
Olumiant	baricitinb	Update to remove Simponi Aria as one of the first line trial and failure options for rheumatoid arthritis indication. Simponi is still an option.	Update	4/01/2021

Rituxan *Truxima (in Rituximab)*	rituximab rituximab-abbs	Update to remove Simponi Aria as one of the first line trial and failure options for rheumatoid arthritis indication. Simponi is still an option.	Update	4/01/2021
Xeljanz/XR	tofacitinib	Update to remove Simponi Aria one of the first line trial and failure options for psoriatic arthritis indication. Simponi is still an option. Tremfya has been added as another first line option for psoriatic arthritis. Remove infliximab as one of the trial and failure options for ulcerative colitis.	Update	4/01/2021
Taltz	ixekizumab	Update to remove Simponi Aria as one of the first line trial and failure options for psoriatic arthritis and ankylosing spondylitis indications. Simponi is still an option.	Update	4/01/2021
Cosentyx	secukinumab	Update to remove Simponi Aria one of the first line trial and failure options for psoriatic arthritis and ankylosing spondylitis indication. Simponi is still an option.	Update	4/01/2021
Entyvio	vedolizumab	Update to remove infliximab as one of the trial and failure options for ulcerative colitis and Crohn's disease.	Update	4/01/2021
Ilumya	tildrakizumab-asmn	Update psoriasis reauthorization criteria: A documentation of positive clinical response to therapy as evidence by one of the following: **1)** Reduction of body surface area involvement from baseline **2)** Improvement in symptoms (e.g., severe itching, inflammation) from baseline.	Update	4/01/2021
Otezla	apremilast	Update psoriasis reauthorization criteria: A documentation of positive clinical response to therapy as evidenced by one of the following: **1)** Reduction of body surface area involvement from baseline **2)** Improvement in symptoms (e.g., severe itiching, inflammation) from baseline.	Update	4/01/2021

Siliq	brodalumab	Update psoriasis reauthorization criteria: A documentation of positive clinical response to therapy as evidenced by one of the following: **1)** Reduction of body surface area involvement from baseline **2)** Improvement in symptoms (e.g., severe itching, inflammation) from baseline.	Update	4/01/2021
Skyrizi	risankizumab-rzaa	Update psoriasis reauthorization criteria: A documentation of positive clinical response to therapy as evidenced by one of the following: **1)** Reduction of body surface area involvement from baseline **2)** Improvement in symptoms (e.g., severe itching, inflammation) from baseline.	Update	4/01/2021
Stelara	ustekinumab	Update psoriasis reauthorization criteria: A documentation of positive clinical response to therapy as evidenced by one of the following: Reduction of body surface area involvement from baseline Improvement in symptoms (e.g., severe itching, inflammation) from baseline.	Update	4/01/2021
Isturisa	osilodrostat	Requirement of trial and failure to 90 days of ketoconazole tablets.	Update	4/01/2021
Sabril *Vigadrone*	vigabatrin	Allow *either* the trial and failure of two formulary anticonvulsants *or* for continuation of therapy.	Update	4/01/2021
Copper Chelating Agents	trientine pencillamine	For Cuprimine, generic penicillamine, Syprine, trientine, Clovique for Wilson's Disease, added Documentation of one of the following diagnostic tests: 1) Presence of Kayser-Fleisher rings 2) Serum ceuloplasim (CPN) less than 20 mg/dL 2) 24-hour urinary copper excretion greater than 100 mcg	Update	4/01/2021

		3) Liver biopsy with copper dry weight greater than 250 mcg/g 4) ATP7B mutation via genetic testing AND Prescribed by gastroenterologist or hepatologist For Cuprimine and generic penicillamine for cystinuria indication, added: **1)** Requirement of trial and failure of urinary alkalinization therapy **2)** Prescribed by nephrologist or urologist For Cuprimine and generic penicillamine for rheumatoid arthritis indication must be prescribed by rheumatologist.		
Provigil	Modafinil	An exception to the quantity limit to allow for twice daily dosing for use in excessive somnolence-narcolepsy.	Update	4/01/2021
Nubeqa	daralutamide	Reauthorization criteria will state 'patient does not show evidence of progressive disease while on therapy."	Update	4/01/2021